Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Monday . The stock had previously closed at $21.30, but opened at $23.15. Ascentage Pharma Group International shares last traded at $23.5530, with a volume of 973 shares.

Wall Street Analyst Weigh In

AAPG has been the topic of a number of research analyst reports. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective on the stock. Oppenheimer initiated coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price for the company. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. Based on data from MarketBeat, Ascentage Pharma Group International presently has an average rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Stock Up 1.8%

The firm’s 50 day simple moving average is $24.01 and its 200 day simple moving average is $29.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Thursday, March 26th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million for the quarter.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently modified their holdings of AAPG. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Tema Etfs LLC acquired a new stake in Ascentage Pharma Group International during the second quarter worth about $610,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International during the third quarter valued at approximately $96,000. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International during the third quarter valued at approximately $204,000. Finally, UBS Group AG lifted its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.